Antisense Therapeutics to Present at Rodman & Renshaw 9th Annual Healthcare Conference
MELBOURNE, AUSTRALIA--(Marketwire - October 23, 2007) - Antisense Therapeutics Limited (ASX: ANP) today announced that the Company is scheduled to present at the Rodman
& Renshaw 9th Annual Global Healthcare Conference, on November 5-7, in New
York City.
Mark Diamond, Antisense Therapeutics Chief Executive Officer, will give a
presentation on November 7, at 8:50 a.m. EST on the Company and its lead
compound, ATL1102, which is currently in Phase IIa clinical trials as a
treatment for multiple sclerosis (MS). The presentation will be followed
by a question and answer session and a live webcast may be accessed at the
Company's website, www.antisense.com.au, or at
http://wsw.com/webcast/rrshq12/anp.au.
A replay of the presentation will be archived for 90 days after the
conference, at the same locations. For more information about the Rodman &
Renshaw 9th Annual Healthcare Conference, please visit Rodman & Renshaw's
website at www.rodmanandrenshaw.com.
Antisense management will be available for meetings in New York on November
7-9.
The Company's current Phase IIa trial is a study in 80 patients to assess
the safety and efficacy of ATL1102 as a treatment for relapsing remitting
MS.
ATL1102 is a second-generation antisense inhibitor of CD49d, a subunit of
VLA-4 (Very Late Antigen-4). It is believed that the inhibition of VLA-4
prevents white blood cells from entering sites of inflammation, thereby
halting the progression of inflammatory diseases such as MS. VLA-4 is a
clinically validated target in the treatment of MS. Antisense inhibition
of VLA-4 has demonstrated positive effects in an animal model of MS and the
data has been published - Myers et al., J Neuroimmunol 160, 12-24 (2005).
About Antisense Therapeutics Limited
Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed
biopharmaceutical drug discovery and development company. Its mission is
to create, develop and commercialise novel antisense pharmaceuticals for
large unmet markets. ANP's major shareholders include Circadian
Technologies Limited (ASX: CIR) and Antisense Therapeutics' strategic
technology partner, Isis Pharmaceuticals Inc.
Website: www.antisense.com.au
Contact Information: Contact Information
US Investors:
Andrea Costa
The Global Consulting Group
(646) 284-9461
acosta@hfgcg.com
Company:
Mark Diamond
Managing Director
+61 3 9827 8999